XNCR

Xencor, Inc. (XNCR) Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics for cancer and autoimmune diseases. The company operates as a single reportable segment and relies on collaboration agreements, milestone payments, and royalties for revenue, as it has not yet commercialized any internally developed products.

Key Financial Metrics

Note: Liquidity includes cash, cash equivalents, and marketable debt securities. Debt consists primarily of liabilities related to the sale of future royalties.

Material Changes vs. Prior Period

• Revenue Volatility: Q2 2026 revenue increased by $7.6 million compared to Q2 2025, driven by a $27.6 million royalty recognition from a settlement with Alexion regarding U.S. Ultomiris royalties. However, YTD revenue decreased by $20.6 million due to lower milestone receipts compared to the prior year.
• Expense Growth: Research and Development (R&D) expenses increased by $10.2 million in Q2 and $16.3 million YTD, primarily due to higher external costs for clinical programs (XmAb942, XmAb819) and internal costs.
• Investment Fluctuations: The company recorded a $18.1 million unrealized gain on marketable equity securities (Zenas BioPharma) in Q2 2026, contrasting with a $33.9 million unrealized loss YTD 2026. This volatility significantly impacted "Other income (expense), net."
• Cash Flow: Net cash used in operating activities increased to $123.3 million YTD 2026 from $52.6 million YTD 2025, reflecting higher operating expenditures and lower milestone collections.

Guidance, Outlook, and Risks

• Settlement Impact: On July 29, 2026 (subsequent to period end), Xencor settled a dispute with Alexion. The company will receive $105.0 million in two installments ($52.5 million in August 2026 and the remainder one year later). Following this, Alexion has no further obligation to pay royalties on U.S. Ultomiris sales, though ex-U.S. royalties continue.
• Liquidity Outlook: Management believes current resources ($486.4 million in cash and marketable securities as of June 30, 2026) are sufficient to fund operations through at least the next 12 months and potentially through 2028, assuming current plans hold.
• Key Risks:
  • Dependence on collaboration partners (Alexion, Incyte, Zenas) for revenue milestones and royalties.
  • Uncertainty regarding clinical trial outcomes for internal pipeline candidates (e.g., XmAb819, XmAb541).
  • Volatility in the fair value of equity investments (Zenas BioPharma).
  • Historical material weaknesses in internal controls (though management concluded controls were effective as of June 30, 2026).
• Unusual Items: The Q2 results include a significant non-cash royalty revenue adjustment related to the Alexion dispute resolution. Additionally, the company recorded $0.8 million in asset impairment charges related to discontinued programs.

Investor Verification Checklist

• Alexion Settlement Terms: Verify the timing and certainty of the $105.0 million settlement payments and the cessation of future U.S. Ultomiris royalties.
• Zenas Investment Valuation: Review the fair value assumptions for the Zenas BioPharma equity stake, which caused significant swings in other income/expense.
• Royalty Sale Liabilities: Confirm the effective interest rates (19.0% for Ultomiris, 18.5% for Monjuvi) and the impact of the Monjuvi royalty cap being reached on future cash flows.
• Cash Burn Rate: Assess the sustainability of the $123.3 million YTD operating cash burn against the $456.5 million liquidity position.
• Clinical Milestones: Monitor upcoming data readouts for XmAb541 (ovarian cancer) and XmAb942 (ulcerative colitis) which could trigger future milestone payments or require additional capital.